194 related articles for article (PubMed ID: 18570366)
1. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
Zhou N; Moradei O; Raeppel S; Leit S; Frechette S; Gaudette F; Paquin I; Bernstein N; Bouchain G; Vaisburg A; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Lu A; Rahil J; MacLeod AR; Li Z; Besterman JM; Delorme D
J Med Chem; 2008 Jul; 51(14):4072-5. PubMed ID: 18570366
[TBL] [Abstract][Full Text] [Related]
2. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
[TBL] [Abstract][Full Text] [Related]
4. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D
Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.
Chia K; Beamish H; Jafferi K; Gabrielli B
Mol Pharmacol; 2010 Sep; 78(3):436-43. PubMed ID: 20538840
[TBL] [Abstract][Full Text] [Related]
6. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
[TBL] [Abstract][Full Text] [Related]
7. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.
Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416
[TBL] [Abstract][Full Text] [Related]
8. N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.
Xu YJ; Miao HQ; Pan W; Navarro EC; Tonra JR; Mitelman S; Camara MM; Deevi DS; Kiselyov AS; Kussie P; Wong WC; Liu H
Bioorg Med Chem Lett; 2006 Jan; 16(2):404-8. PubMed ID: 16246551
[TBL] [Abstract][Full Text] [Related]
9. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
10. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
[TBL] [Abstract][Full Text] [Related]
11. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
Suzuki T; Ando T; Tsuchiya K; Fukazawa N; Saito A; Mariko Y; Yamashita T; Nakanishi O
J Med Chem; 1999 Jul; 42(15):3001-3. PubMed ID: 10425110
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
[TBL] [Abstract][Full Text] [Related]
14. Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Assem el-SK; Peh KH; Wan BY; Middleton BJ; Dines J; Marson CM
Int Immunopharmacol; 2008 Dec; 8(13-14):1793-801. PubMed ID: 18805511
[TBL] [Abstract][Full Text] [Related]
15. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities.
Maeda T; Nagaoka Y; Kuwajima H; Seno C; Maruyama S; Kurotaki M; Uesato S
Bioorg Med Chem; 2004 Aug; 12(16):4351-60. PubMed ID: 15265487
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Kell J
Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
[TBL] [Abstract][Full Text] [Related]
18. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors.
Chen Y; He R; Chen Y; D'Annibale MA; Langley B; Kozikowski AP
ChemMedChem; 2009 May; 4(5):842-52. PubMed ID: 19350613
[TBL] [Abstract][Full Text] [Related]
19. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
